Michael Miedema Minneapolis Heart Institute Foundation

Michael Miedema, MD, MPH

Director, Nolan Family Center for Cardiovascular Health

Dr. Michael Miedema is director of the Nolan Family Center for Cardiovascular Health at Minneapolis Heart Institute Foundation and director of cardiovascular prevention at Minneapolis Heart Institute®. Dr. Miedema obtained his medical degree and completed a cardiovascular fellowship at the University of Minnesota Medical School and also has a master’s degree in public health from the Harvard School of Public Health. He is a leading national expert in cardiovascular prevention. He serves as an Associate Editor for the digital content for the Prevention Section of the American College of Cardiology. He served on the executive review committee for the 2018 ACC/AHA Cholesterol Guidelines, and was a member of the 2019 ACC/AHA Guidelines Committee for the Primary Prevention of cardiovascular disease.

Back to Prevention Team

Michael Miedema Minneapolis Heart Institute Foundation
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.